Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-XH06
- Development stage
- Unknown
- Lead developer
- Huazhong University of Science and Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
131I-XH06 is a glypican-3 (GPC3)-targeted radioligand therapy being developed for the treatment of hepatocellular carcinoma (HCC). It consists of an anti-GPC3 single-chain variable fragment (scFv) precursor, designated XH06, radiolabeled with the beta- and gamma-emitting radioisotope iodine-131 (131I). GPC3 is a cell-surface oncofetal glycoprotein highly overexpressed in HCC but minimally expressed in normal tissues, making it an ideal target for theranostic applications. By binding specifically to GPC3-expressing tumor cells, 131I-XH06 delivers targeted radiation to induce DNA damage and tumor cell death, while also allowing for SPECT/CT imaging to monitor biodistribution and tumor targeting.
- Other names
- 131I-aGPC3-scFviodine-131 XH06iodine131 XH06iodine 131 XH06
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on 131I-XH06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-XH06.